GILEAD SCIENCES, INC. for GILEAD SCIENCES INC
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 3rd Quarter - Report (this page) | Oct 20, 2026 | $6,580,000 | Replaced |
| 3rd Quarter - Amendment | Oct 21, 2026 | $2,320,000 | Yes |
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Advocate on domestic and global drug pricing proposals, international trade and protection of intellectual property; global supply chain issues, including the Medical Supply Chain Resiliency Act and tariffs; compulsory licensing and other IP issues in multiple countries.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BILL BODE | — |
| MICHAEL D BOYD | — |
| JAIMON JACKSON | — |
| DAVID PULLIAM | — |
| GRACE RODDEN | — |
| RILEY SWINEHART | — |
| RICHARD WHITE | — |
Health Issues HCR
Advocate on drug pricing proposals. Proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BILL BODE | — |
| MICHAEL D BOYD | — |
| ANNA GRIFFIN | — |
| JAIMON JACKSON | — |
| DAVID PULLIAM | — |
| GRACE RODDEN | — |
| RILEY SWINEHART | — |
| RICHARD WHITE | — |
Medicare/Medicaid MMM
Advocate for provisions modifying the Inflation Reduction Act and other drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies and prevention including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules, including those related to payments in Medicare, Medicaid drug rebates, and proposed CMMI demonstrations.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BILL BODE | — |
| MICHAEL D BOYD | — |
| ANNA GRIFFIN | — |
| JAIMON JACKSON | — |
| DAVID PULLIAM | — |
| GRACE RODDEN | — |
| RILEY SWINEHART | — |
| RICHARD WHITE | — |
Copyright/Patent/Trademark CPT
Issues related to pharmaceuticals and intellectual property protection including technology transfer, patent rights and funding.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BILL BODE | — |
| DAVID PULLIAM | — |
| GRACE RODDEN | — |
| RICHARD WHITE | — |
Budget/Appropriations BUD
Funding for policies relating to domestic and international HIV, Hepatitis C, oncology, and public health activities via appropriations. Advocacy regarding drug pricing proposals, including provisions modifying the Inflation Reduction Act and government purchasing proposals.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BILL BODE | — |
| JAIMON JACKSON | — |
| DAVID PULLIAM | — |
| GRACE RODDEN | — |
| RILEY SWINEHART | — |
| RICHARD WHITE | — |
Taxation/Internal Revenue Code TAX
Legislative and regulatory proposals to change international and domestic corporate tax law and policy.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID PULLIAM | — |
| GRACE RODDEN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.